We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BGI and Diagenode SA Collaborate to Implement Standard Methods in Epigenetics and Next Generation Sequencing Sample Preparation

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Bioruptor NGS BGI and Diagenode SA have announced that they will enter into a close collaboration for the implementation of standard methods in epigenetics and next generation sequencing sample preparation.

Diagenode will provide BGI with early access to its new developments in chromatin or DNA methylation analysis methods and tools.

Diagenode aims to increase the consistency and precision of enrichment assays, such as ChIP, MeDIP, MBD capture, bisulfite conversion, and DNA fragmentation, prior to next generation sequencing.

"Consistency is extremely important, not only for saving reagents and precious samples, but also for creating universal high standards in the emerging field of epigenetics," said Didier Allaer, CEO of Diagenode. "We are very proud to be partnering with BGI in these domains."

"We have been successfully using Diagenode's Bioruptors® and reagents for epigenetics, and in exon sequencing, for years now and have implemented them in all of our facilities across China. We are delighted to be able to expand our collaboration with Diagenode, whose reliability and creativity for improving consistency is proven," said Jihua Sun, Lead of Epigenetics Sequencing Platform, and Renhua Wu, Lead of Exon Sequencing Platform of BGI-Shenzhen.